- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.08. | H.C. Wainwright bestätigt Kaufempfehlung für Medicenna mit Kursziel von 2,50 $ | - | Investing.com Deutsch | ||
| 04.08. | H.C. Wainwright reiterates Buy rating on Medicenna stock, maintains $2.50 target | 1 | Investing.com | ||
| 04.08. | H.C. Wainwright reiterates Buy rating on Medicenna stock with $2.50 target | 1 | Investing.com | ||
| 01.08. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 01.08. | Medicenna Therapeutics Corp. Q1 Loss Rises | 1 | RTTNews | ||
| 01.08. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights | 88 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our... ► Artikel lesen | |
| 31.07. | Stocks in Play: Medicenna Therapeutics Corp | - | Baystreet.ca | ||
| 26.06. | Medicenna Therapeutics GAAP EPS of -C$0.15 | 3 | Seeking Alpha | ||
| 26.06. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights | 287 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA®... ► Artikel lesen | |
| 01.05. | Medicenna Therapeutics Corp: Medicenna presents preclinical MDNA113 data at meeting | 1 | Stockwatch | ||
| 29.04. | Medicenna Therapeutics Corp: Medicenna's MDNA11 showing acceptable safety profile | 1 | Stockwatch | ||
| 29.04. | Medicenna Therapeutics has "elegant science", Research Capital says | 2 | Cantech Letter | ||
| 22.04. | Stocks in Play: Medicenna Therapeutics Corp. | 2 | Baystreet.ca | ||
| 26.03. | Medicenna Therapeutics Corp: Medicenna to present MDNA11 update at AACR | 1 | Stockwatch | ||
| 26.03. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 25.02. | Medicenna Therapeutics Corp: Medicenna talks MDNA11 Ability-1 study data | 1 | Stockwatch | ||
| 13.02. | Medicenna Therapeutics Corp.: Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones | 172 | GlobeNewswire (Europe) | - Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck's (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1... ► Artikel lesen | |
| 05.12.24 | Medicenna Therapeutics Corp.: Medicenna Provides Clinical Update and Announces First Complete Response in MDNA11 in Combination with KEYTRUDA (pembrolizumab) Dose Escalation Arm of the ABILITY-1 Study | 180 | GlobeNewswire (Europe) | 70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck's (known as MSD outside of the US and Canada)... ► Artikel lesen | |
| 15.11.24 | Medicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update | 218 | GlobeNewswire (Europe) | MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression... ► Artikel lesen | |
| 11.11.24 | Medicenna Therapeutics Corp.: Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA (pembrolizumab) at the ... | 182 | GlobeNewswire (Europe) | Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression with... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| THARIMMUNE | 3,630 | 0,00 % | Tharimmune Inc.: Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments | RED BANK, NJ / ACCESS Newswire / August 20, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic... ► Artikel lesen | |
| BEAM THERAPEUTICS | 16,060 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| NUVALENT | 73,24 | 0,00 % | Piper Sandler initiates Nuvalent stock coverage with Overweight rating | ||
| EVOTEC | 6,080 | -2,94 % | Evotec-Aktie: Neue Tiefs in Sicht? Nur ein Wunder kann jetzt wohl noch helfen! | © Foto: Foto von Anna Shvets auf PexelsDie Hamburger Biotechfirma Evotec kämpft ums Überleben. Das traditionelle Geschäft mit der Wirkstoffforschung bricht weg, während die hochgelobte Biologics-Sparte... ► Artikel lesen | |
| QIAGEN | 42,290 | +0,05 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen nach einer Investorenveranstaltung auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Das Interesse der Teilnehmer... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 14,600 | +5,87 % | ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales | ||
| VIKING THERAPEUTICS | 22,035 | -0,02 % | Viking Therapeutics-Aktie: +50% nach Kauftipp Anfang Juli! | Nächster Volltreffer unserer Biotech-Profis: Anfang Juli haben wir auf die großen Kurschancen bei der Aktie von Viking Therapeutics aufmerksam gemacht. Inzwischen notiert das Papier rund +50% höher... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,765 | 0,00 % | Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid | ||
| BIONTECH | 95,40 | -0,05 % | CureVac vor Übernahme durch BioNTech: Geringerer Verlust im ersten Halbjahr | CureVac hat im zweiten Quartal 2025 einen Umsatz von 1,2 Millionen Euro erzielt, nach 14,4 Millionen Euro im Vorjahreszeitraum. Der operative Verlust verringerte sich auf 61,7 Millionen Euro, nach 73... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 18,565 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize... ► Artikel lesen | |
| TANGO THERAPEUTICS | 6,750 | -3,02 % | Piper Sandler startet Coverage für Tango Therapeutics mit "Overweight" | ||
| KEROS THERAPEUTICS | 14,230 | 0,00 % | Keros Therapeutics, Inc.: Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy | LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,880 | 0,00 % | Summit Therapeutics: Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 | Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,330 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| VERA THERAPEUTICS | 22,120 | +0,23 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen |
MEDICENNA THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.